Saturday, 10 May 2025
  
Login

Australia's most trusted
source of pharma news

Saturday, 10 May 2025
News

Lilly eyes off a first-to-market

Posted 2 March 2023 AM

After splashing US$1 billion on Gavreto, Roche has decided to return development and commercialisation rights of the drug, excluding Greater China, to Blueprint Medicines (BPM).

The decision could give Lilly a jump on becoming the first company to launch a RET-altered cancer medicine in Australia with Retevmo, considering that BPM is yet to register a product in Australia and has no local presence.

To see the whole article, please login

Popular

What downturn? Pharma is back
How leaders can fix disengagement
Who's industry's 'Most Influential'?
Drug flood overwhelming HCPs
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home